Home » Economy » +++ Exchange ticker +++ – Swiss exchange continues to expand price gains News

+++ Exchange ticker +++ – Swiss exchange continues to expand price gains News

Tuesday, September 12th, 2017 | Economy

The Swiss Market Index (SMI) gains 0.6% to 9'037 points by 13.00 hrs. The market is supported by the Index Heavyweights Roche (+ 0.6%). The titles recover somewhat on Tuesday from the setback that they had suffered because of the failure of primary endpoints with the drugs Zelobraf and Lampalizumab.
Credit Suisse continued to expand its leadership position at + 2.8%, followed by LafargeHolcim (+ 1.2%) and Adecco (+ 1.1%). The CS shares have risen in the favor of the analysts of Société Générale.
By far the strongest price gains were achieved by Dormakaba (+ 9.6%) and Partners Group (+ 5.3%), which posted better than expected annual and half-year figures. Kepler has significantly increased the price target for Partners Group following the results publication.
Read the full lunch report here.
Higher than expected out-of-date inflation data in the UK give the pound sterling a strong boost. It is rising by 0.8 percent to a six-week high of 1.3262 dollars. Consumer prices rose by 2.9 percent in August in the UK. According to traders, speculation is fueling a rate hike.
U.K. stocks edge higher, but strong pound is a cap on gains https://t.co/PfKNuRoxwf
– MarketWatch (@MarketWatch) September 12, 2017
Investors on the Swiss stock exchange continue to pick up.
The Swiss Market Index (SMI) gained 0.7% to 10'046 points against 10.20. The broad Swiss Performance Index (SPI) fell by 0.8% to 10'334 points.
By far the strongest share price gains of + 5.2% are the partnerships of Partners Group. Among the blue chips, Credit Suisse (+ 2.2%) and Zurich Insurance (+ 0.9%) list the price winners.

SMI, 12.9.2017, Source: cash.ch
After his strong week's start, the Dax has been on the forward course on Tuesday. It immediately surpassed the opening of the mark of 12 500 points. Lastly, the German leading index stood at 0.336 percent higher at 12 520.64 points.
Börse Frankfurt: Cars in the focus of the Dax investors – the buy-in on the stock market continues. The Dax is calculated according to … https://t.co/7lACubUHVI
– Trade Fairs (@hb_finances) 12 September 2017
Deutsche Bank get backwind by a graduation. The shares are up 1.2 percent to a two and a half week high of 13.87 euros. According to traders, analysts of the KBW investment bank have raised the shares to "outperform" from "marketperform", the price target is 19 euros.
The SMI stands at 9019 points shortly after stock market opening, which is 0.4 percent more than last night. Analysts at Société Générale have taken a positive stance against the CS shares (+2.6 percent) and are now recommending them to hold a higher price target (so far hold). At the same time, they have reduced the price target for the UBS securities (+0.2 percent), but they continue to place the shares with Buy.
Zurich (+0.9 per cent) and Swiss Re (+0.2 per cent) are advancing in connection with "Irma", since the damage caused by the cyclone is expected to be smaller than previously expected. The other insurance values ​​are also more modest. Swiss Life (+0.2 percent), Bâloise (+0.2 percent) and Helvetia (-0.1 percent) are developing differently. Bâloise and Helvetia received new course objectives from Goldman Sachs. The analysts cut their health expectations for Helvetia, but they are increasing it for Bâloise. However, the experts still recommend the former to buy, while they classify the latter with neutral.
After the Esmo trade congress, which ended on Monday, some shifting and reappraisals in the pharmaceutical and healthcare sectors are likely to occur. A first indication of this is a reduction in the price of Roche (+0.5 percent) by HSBC. Branchneachbar Novartis (+0.3 percent) reported that his daughter Sandoz with the Biosimilar Rituximab an important step forward. Because the US health authority FDA has accepted the approval application and is now reviewing it.

The #Partners Group makes analysts speechless – in the positive sense. # Asset management Private #Equity #Zug #Baar https://t.co/hrLCFLfDcX
– cash (@cashch) September 12, 2017

Partners Group (+5.2 per cent) are picking up considerably after half-year figures. The financial market specialist once again exceeded all expectations. Traders go from new record values ​​for the securities in the course of the day.
In the broad market Basilea (+0.6 percent) and Dormakaba (+8 percent) show the price increases. Dormakaba presented annual results that exceeded the analysts' forecasts. Basilea, in turn, has signed a sales agreement with the company Cardiome Pharma for the antibiotic Zevtera / Mabelio (ceftobiprole) in Europe (excluding Nordic countries) and in Israel.
The focus of the investors are also AMS, since in the evening Apple will present ten years after the introduction of the first iPhone generation a new device. AMS is a supplier to Apple's iPhone.
Meanwhile, the stock exchanges are closed in the Far East. Investors covered on Tuesday mainly with papers of insurance companies and banks. The Japanese lead index Nikkei closed 1.2 percent higher at 19'776 points. The broader topix climbed 0.9 percent to 1627 counts. The MSCI index for equities outside Japan has temporarily risen to the highest level in ten years.
According to the pre-market data of Julius Baer, ​​the SMI increases by 0.14 percent to 8995 points. In view of the less dramatic than feared storm damage in Florida, Zurich Insurance (+1 percent) is again growing significantly. J.P. Morgan raised the stock to "overweight". Swiss Re (+0.6 percent) is also among the best in the market. The remaining SMI shares are also positive.
There are few news from the large groups: Novartis (+0.3 percent) reported that the subsidiary Sandoz in the generics business with the active ingredient Rituximab had a success.
In the broad market, however, several companies have presented their figures: Dormakaba is showing positive figures in the 2016/17 financial year, while the Partners Group has a successful half-year. However, Romande Energie had to accept a slump in profits.
The euro continued to trade below the 1.20 dollar mark on Tuesday. In the morning the common currency cost 1,1950 dollars, which is slightly less than on Monday evening. The euro held a small gap to the Swiss franc of 1.14 Swiss francs and cost 1.1440 in early trading after 1.1419 Swiss francs the previous evening. The dollar also rose slightly to 0.9572 after 0.9548 CHF. On Thursday, the SNB's position assessment will be on the agenda.
On Tuesday, the Tokyo Stock Exchange increased its share of profits from insurers and good Wall Street regulations. The Nikkei of the 225 leading figures is currently 1.1 percent higher at 19'762 points.
Investors were relieved that the hurricane "Irma" has weakened and the damage in Florida probably not as strong as feared. In addition, there was a sigh of relief in the North Korean crisis after the country, on the weekend of its Independence Day, had waived a missile test expected by some observers.

The destruction of Hurricane #Irma can be seen after the storm turns several Caribbean islands brown: https://t.co/oTZjRgmdmN pic.twitter.com/Li4MUNNqcR
– NASA (@NASA) September 11, 2017

Shares of insurers, which had recently lost value due to the storms "Harvey" and "Irma", increased in part. The shares of Dai-ichi Life climbed 3.3 percent. Nomura's notes rose by 1.8 percent.
The euro hardly moved in the Far Eastern trade. The single European currency lastly cost $ 1,1962. The US currency rose to 109.35 yen to the yen. The Swiss franc was trading at around 0,9557 francs per dollar and around 1.1433 francs per euro.
(Cash / AWP / Reuters)


Chris Cornell Boots

Chris Cornell Boots Chris Cornell Boots Vlogs Damien Rice – The Blower's Daughter

Praise for the race: Free rain start &qu

The decision shows however in any case the more generous line, which the

CrossFit Games 2017

CrossFit Games 2017 CrossFit Games 2017 Vlogs The Police – Roxanne All you

Rihanna Needed Me

Rihanna Needed Me Rihanna Needed Me Vlogs Everything Wrong With GoldenEye In 14